Roche's Sophie Kornowski joins Chris Viehbacher at Gurnet Point; FDA will give Roche's groundbreaking flu drug speedy review
→ We now know where Sophie Kornowski is headed. The top dealmaking exec at Roche left recently, leaving James Sabry with a chance to move up to the executive committee as he combines the business teams at Roche and its big subsidiary Genentech. Now we’ve learned that Kornowski is joining ex-Sanofi CEO Chris Viehbacher at Gurnet Point Capital. She’ll now concentrate on building up the portfolio with Ernesto Bertarelli’s investment money.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.